← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Abaloparatide

FDA approved · Rx

PTHrP analog, bone anabolic

Also known as: Tymlos, BA058, BIM-44058, abaloparatida, abaloparatidum, BA-058

Evidence score
91/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 25 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Abaloparatide is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), sold under the brand name Tymlos. It acts on the PTH1 receptor and, when given intermittently, is thought to stimulate bone formation more than bone breakdown, increasing bone mineral density.

What the evidence shows

Automatic summaryHuman trials

Abaloparatide is FDA approved for the treatment of osteoporosis in postmenopausal women at high risk of fracture, and later for men with osteoporosis at high risk of fracture, based on randomized trials showing reduced fracture risk and increased bone density. It has about 25 registered human trials, reaching Phase 4, and a substantial published literature. Evidence for uses beyond osteoporosis is not established.

Key facts

Molecular formula
C174H300N56O49
Molecular weight
3961 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

25registered studies
Phase 4most advanced phase
14completed (sample)
2recruiting (sample)

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Phase 3CompletedNCT04064411

PTH Analog Type II Odontoid Fracture

Phase 2TerminatedNCT04760782

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Phase 2CompletedNCT01674621

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

Phase 1CompletedNCT04936984

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

405papers referencing Abaloparatide

Osteoporosis.

Lancet2019

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

JAMA2016

Drug therapy for osteoporosis in older adults.

Lancet2022

Osteoporosis in Older Adults.

Med Clin North Am2020

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.